Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin’s PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to a placebo in disease-free survival in patients …read more.